Antitumor effects of droloxifene, a new antiestrogen drug, against 7,12-dimethylbenz(a)anthracene-induced mammary tumors in rats
- PMID: 1812300
- DOI: 10.1254/jjp.57.215
Antitumor effects of droloxifene, a new antiestrogen drug, against 7,12-dimethylbenz(a)anthracene-induced mammary tumors in rats
Abstract
The antitumor effects of droloxifene (DROL, (E)-alpha-[p-[2-(dimethylamino)ethoxy]-phenyl]-alpha-ethyl-3-stilbeno l), a new antiestrogen drug, on 7,12-dimethylbenz(a)anthracene (DMBA)-induced estrogen-dependent mammary tumors in rats were studied and compared with those of tamoxifen (TAM). Mammary tumors appeared from about 2 months after p.o. administration of DMBA to female rats, and all of them were estrogen receptor (ER) and progesterone receptor positive. DROL and TAM (p.o.) inhibited the growth of the tumors. Both drugs inhibited the binding of 125I-estradiol-17 beta to ER in the cytosol of the tumor in vitro, and the effect of DROL was much stronger than that of TAM. When 3H-estradiol-17 beta (3H-E2) was given s.c. to rats with the mammary tumors, 3H-E2 accumulated in the tumors, uteri and vaginae in which the ER levels are known to be high, but was low in the heart, in which the ER levels are normally low. DROL and TAM decreased the levels of 3H-E2 in the tumors, uteri and vaginae, but had no effect in the hearts. When DROL or TAM was given p.o. to rats daily for 7 consecutive days after administration of DMBA, they inhibited the induction of mammary tumors by DMBA. From these results, DROL inhibits the growth and the initiation of DMBA-induced mammary tumors by inhibiting the binding of estrogen to its receptor.
Similar articles
-
Binding sites of droloxifene in the cytosol of 7,12-dimethylbenz[a]anthracene-induced rat mammary tumor cells.Jpn J Cancer Res. 1994 Jun;85(6):639-44. doi: 10.1111/j.1349-7006.1994.tb02407.x. Jpn J Cancer Res. 1994. PMID: 8063618 Free PMC article.
-
The estrogenic and antiestrogenic activities of droloxifene in human breast cancers.Jpn J Pharmacol. 1993 Sep;63(1):27-34. doi: 10.1254/jjp.63.27. Jpn J Pharmacol. 1993. PMID: 8271528
-
Inhibitory effects of medroxyprogesterone acetate (MPA) and the pure antiestrogen EM-219 on estrone (E1)-stimulated growth of dimethylbenz(a)anthracene (DMBA)-induced mammary carcinoma in the rat.Breast Cancer Res Treat. 1995 May;34(2):147-59. doi: 10.1007/BF00665787. Breast Cancer Res Treat. 1995. PMID: 7647332
-
Pharmacology of tamoxifen in laboratory animals.Cancer Treat Rep. 1980 Jun-Jul;64(6-7):745-59. Cancer Treat Rep. 1980. PMID: 6775807 Review.
-
EM-652 (SCH 57068), a third generation SERM acting as pure antiestrogen in the mammary gland and endometrium.J Steroid Biochem Mol Biol. 1999 Apr-Jun;69(1-6):51-84. doi: 10.1016/s0960-0760(99)00065-5. J Steroid Biochem Mol Biol. 1999. PMID: 10418981 Review.
Cited by
-
Binding sites of droloxifene in the cytosol of 7,12-dimethylbenz[a]anthracene-induced rat mammary tumor cells.Jpn J Cancer Res. 1994 Jun;85(6):639-44. doi: 10.1111/j.1349-7006.1994.tb02407.x. Jpn J Cancer Res. 1994. PMID: 8063618 Free PMC article.
-
Pharmacokinetics of droloxifene in mice, rats, monkeys, premenopausal and postmenopausal patients.Eur J Drug Metab Pharmacokinet. 1994 Jan-Mar;19(1):47-58. doi: 10.1007/BF03188823. Eur J Drug Metab Pharmacokinet. 1994. PMID: 7957452 Clinical Trial.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
